Shopping Cart 0
Cart Subtotal
AED 0

Peritoneal Cancer - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Peritoneal Cancer-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer-Pipeline Review, H2 2018, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 14, 78, 52, 17, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 7 and 1 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 7

Peritoneal Cancer-Overview 8

Peritoneal Cancer-Therapeutics Development 9

Peritoneal Cancer-Therapeutics Assessment 29

Peritoneal Cancer-Companies Involved in Therapeutics Development 45

Peritoneal Cancer-Drug Profiles 93

Peritoneal Cancer-Dormant Projects 1182

Peritoneal Cancer-Discontinued Products 1187

Peritoneal Cancer-Product Development Milestones 1189

Appendix 1201


List Of Figure

List of Figures

Number of Products under Development for Peritoneal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Peritoneal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Peritoneal Cancer-Pipeline by 3-V Biosciences Inc, H2 2018

Peritoneal Cancer-Pipeline by AbbVie Inc, H2 2018

Peritoneal Cancer-Pipeline by Advenchen Laboratories LLC, H2 2018

Peritoneal Cancer-Pipeline by AiVita Biomedical Inc, H2 2018

Peritoneal Cancer-Pipeline by Aldeyra Therapeutics Inc, H2 2018

Peritoneal Cancer-Pipeline by Altor BioScience Corp, H2 2018

Peritoneal Cancer-Pipeline by ALX Oncology Inc, H2 2018

Peritoneal Cancer-Pipeline by Amgen Inc, H2 2018

Peritoneal Cancer-Pipeline by Arrien Pharmaceuticals LLC, H2 2018

Peritoneal Cancer-Pipeline by Astellas Pharma Inc, H2 2018

Peritoneal Cancer-Pipeline by Astex Pharmaceuticals Inc, H2 2018

Peritoneal Cancer-Pipeline by AstraZeneca Plc, H2 2018

Peritoneal Cancer-Pipeline by Atara Biotherapeutics Inc, H2 2018

Peritoneal Cancer-Pipeline by Bayer AG, H2 2018

Peritoneal Cancer-Pipeline by BeiGene Ltd, H2 2018

Peritoneal Cancer-Pipeline by Biocon Ltd, H2 2018

Peritoneal Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Peritoneal Cancer-Pipeline by Boston Biomedical Inc, H2 2018

Peritoneal Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2018

Peritoneal Cancer-Pipeline by Celgene Corp, H2 2018

Peritoneal Cancer-Pipeline by Celsion Corp, H2 2018

Peritoneal Cancer-Pipeline by CerRx Inc, H2 2018

Peritoneal Cancer-Pipeline by Chipscreen Biosciences Ltd, H2 2018

Peritoneal Cancer-Pipeline by Clovis Oncology Inc, H2 2018

Peritoneal Cancer-Pipeline by Corcept Therapeutics Inc, H2 2018

Peritoneal Cancer-Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

Peritoneal Cancer-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Peritoneal Cancer-Pipeline by Eisai Co Ltd, H2 2018

Peritoneal Cancer-Pipeline by Eli Lilly and Co, H2 2018

Peritoneal Cancer-Pipeline by EpiThany Inc, H2 2018

Peritoneal Cancer-Pipeline by Epizyme Inc, H2 2018

Peritoneal Cancer-Pipeline by Exelixis Inc, H2 2018

Peritoneal Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Peritoneal Cancer-Pipeline by Fate Therapeutics Inc, H2 2018

Peritoneal Cancer-Pipeline by Forty Seven Inc, H2 2018

Peritoneal Cancer-Pipeline by Gene Techno Science Co Ltd, H2 2018

Peritoneal Cancer-Pipeline by Genelux Corp, H2 2018

Peritoneal Cancer-Pipeline by Genmab A/S, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Peritoneal Cancer Therapeutic Products under Development, Key Players in Peritoneal Cancer Therapeutics, Peritoneal Cancer Pipeline Overview, Peritoneal Cancer Pipeline, Peritoneal Cancer Pipeline Assessment


Companies

3-V Biosciences Inc

AbbVie Inc

Advenchen Laboratories LLC

AiVita Biomedical Inc

Aldeyra Therapeutics Inc

Altor BioScience Corp

ALX Oncology Inc

Amgen Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Bayer AG

BeiGene Ltd

Biocon Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celgene Corp

Celsion Corp

CerRx Inc

Chipscreen Biosciences Ltd

Clovis Oncology Inc

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Eli Lilly and Co

EpiThany Inc

Epizyme Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Forty Seven Inc

Gene Techno Science Co Ltd

Genelux Corp

Genmab A/S

GlaxoSmithKline Plc

Gradalis Inc

Hemispherx Biopharma Inc

ImmunoGen Inc

IMV Inc

Innate Pharma SA

InSight Biopharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kyowa Hakko Kirin Co Ltd

Lidds AB

MabVax Therapeutics Holdings Inc

Mateon Therapeutics Inc

MaxCyte Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Morphotek Inc

Morvus Technology Ltd

Mycenax Biotech Inc

NewLink Genetics Corp

Novartis AG

NuCana Plc

Oasmia Pharmaceutical AB

OBI Pharma Inc

Oncobiologics Inc

Oncoinvent AS

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Orano Med LLC

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Polaris Pharmaceuticals Inc

Prescient Therapeutics Ltd

Protheragen Inc

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

Regeneron Pharmaceuticals Inc

Rgenix Inc

Rigel Pharmaceuticals Inc

Samyang Holdings Corp

Sanofi

Sanofi Pasteur SA

SELLAS Life Sciences Group Inc

Soricimed Biopharma Inc

Sotio AS

Sun Pharma Advanced Research Company Ltd

Syndax Pharmaceuticals Inc

Synermore Biologics Co Ltd

Targovax ASA

TESARO Inc

Tyrogenex Inc (Inactive)

Vascular Biogenics Ltd

Verastem Inc

Vyriad Inc

Peritoneal Cancer-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer-Pipeline Review, H2 2018, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 14, 78, 52, 17, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 7 and 1 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 7

Peritoneal Cancer-Overview 8

Peritoneal Cancer-Therapeutics Development 9

Peritoneal Cancer-Therapeutics Assessment 29

Peritoneal Cancer-Companies Involved in Therapeutics Development 45

Peritoneal Cancer-Drug Profiles 93

Peritoneal Cancer-Dormant Projects 1182

Peritoneal Cancer-Discontinued Products 1187

Peritoneal Cancer-Product Development Milestones 1189

Appendix 1201


List Of Figure

List of Figures

Number of Products under Development for Peritoneal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Peritoneal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Peritoneal Cancer-Pipeline by 3-V Biosciences Inc, H2 2018

Peritoneal Cancer-Pipeline by AbbVie Inc, H2 2018

Peritoneal Cancer-Pipeline by Advenchen Laboratories LLC, H2 2018

Peritoneal Cancer-Pipeline by AiVita Biomedical Inc, H2 2018

Peritoneal Cancer-Pipeline by Aldeyra Therapeutics Inc, H2 2018

Peritoneal Cancer-Pipeline by Altor BioScience Corp, H2 2018

Peritoneal Cancer-Pipeline by ALX Oncology Inc, H2 2018

Peritoneal Cancer-Pipeline by Amgen Inc, H2 2018

Peritoneal Cancer-Pipeline by Arrien Pharmaceuticals LLC, H2 2018

Peritoneal Cancer-Pipeline by Astellas Pharma Inc, H2 2018

Peritoneal Cancer-Pipeline by Astex Pharmaceuticals Inc, H2 2018

Peritoneal Cancer-Pipeline by AstraZeneca Plc, H2 2018

Peritoneal Cancer-Pipeline by Atara Biotherapeutics Inc, H2 2018

Peritoneal Cancer-Pipeline by Bayer AG, H2 2018

Peritoneal Cancer-Pipeline by BeiGene Ltd, H2 2018

Peritoneal Cancer-Pipeline by Biocon Ltd, H2 2018

Peritoneal Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Peritoneal Cancer-Pipeline by Boston Biomedical Inc, H2 2018

Peritoneal Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2018

Peritoneal Cancer-Pipeline by Celgene Corp, H2 2018

Peritoneal Cancer-Pipeline by Celsion Corp, H2 2018

Peritoneal Cancer-Pipeline by CerRx Inc, H2 2018

Peritoneal Cancer-Pipeline by Chipscreen Biosciences Ltd, H2 2018

Peritoneal Cancer-Pipeline by Clovis Oncology Inc, H2 2018

Peritoneal Cancer-Pipeline by Corcept Therapeutics Inc, H2 2018

Peritoneal Cancer-Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

Peritoneal Cancer-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Peritoneal Cancer-Pipeline by Eisai Co Ltd, H2 2018

Peritoneal Cancer-Pipeline by Eli Lilly and Co, H2 2018

Peritoneal Cancer-Pipeline by EpiThany Inc, H2 2018

Peritoneal Cancer-Pipeline by Epizyme Inc, H2 2018

Peritoneal Cancer-Pipeline by Exelixis Inc, H2 2018

Peritoneal Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Peritoneal Cancer-Pipeline by Fate Therapeutics Inc, H2 2018

Peritoneal Cancer-Pipeline by Forty Seven Inc, H2 2018

Peritoneal Cancer-Pipeline by Gene Techno Science Co Ltd, H2 2018

Peritoneal Cancer-Pipeline by Genelux Corp, H2 2018

Peritoneal Cancer-Pipeline by Genmab A/S, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Peritoneal Cancer Therapeutic Products under Development, Key Players in Peritoneal Cancer Therapeutics, Peritoneal Cancer Pipeline Overview, Peritoneal Cancer Pipeline, Peritoneal Cancer Pipeline Assessment


Companies

3-V Biosciences Inc

AbbVie Inc

Advenchen Laboratories LLC

AiVita Biomedical Inc

Aldeyra Therapeutics Inc

Altor BioScience Corp

ALX Oncology Inc

Amgen Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Bayer AG

BeiGene Ltd

Biocon Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celgene Corp

Celsion Corp

CerRx Inc

Chipscreen Biosciences Ltd

Clovis Oncology Inc

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Eli Lilly and Co

EpiThany Inc

Epizyme Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Forty Seven Inc

Gene Techno Science Co Ltd

Genelux Corp

Genmab A/S

GlaxoSmithKline Plc

Gradalis Inc

Hemispherx Biopharma Inc

ImmunoGen Inc

IMV Inc

Innate Pharma SA

InSight Biopharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kyowa Hakko Kirin Co Ltd

Lidds AB

MabVax Therapeutics Holdings Inc

Mateon Therapeutics Inc

MaxCyte Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Morphotek Inc

Morvus Technology Ltd

Mycenax Biotech Inc

NewLink Genetics Corp

Novartis AG

NuCana Plc

Oasmia Pharmaceutical AB

OBI Pharma Inc

Oncobiologics Inc

Oncoinvent AS

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Orano Med LLC

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Polaris Pharmaceuticals Inc

Prescient Therapeutics Ltd

Protheragen Inc

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

Regeneron Pharmaceuticals Inc

Rgenix Inc

Rigel Pharmaceuticals Inc

Samyang Holdings Corp

Sanofi

Sanofi Pasteur SA

SELLAS Life Sciences Group Inc

Soricimed Biopharma Inc

Sotio AS

Sun Pharma Advanced Research Company Ltd

Syndax Pharmaceuticals Inc

Synermore Biologics Co Ltd

Targovax ASA

TESARO Inc

Tyrogenex Inc (Inactive)

Vascular Biogenics Ltd

Verastem Inc

Vyriad Inc